Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan

Drug Metabolism and Disposition

Volumn 29, Issue 4 II, 2001, Pages 596-600

  Innocenti, F ^a   Iyer, L ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACYLTRANSFERASE; AMONAFIDE; ANTINEOPLASTIC AGENT; CAFFEINE; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; IRINOTECAN; N ACETYLAMONAFIDE; UNCLASSIFIED DRUG;

ALLELE; CONFERENCE PAPER; CRIGLER NAJJAR SYNDROME; DRUG GLUCURONIDATION; DRUG METABOLISM; GENE ACTIVITY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; GILBERT DISEASE; HYPERBILIRUBINEMIA; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; HUMANS; IMIDES; ISOQUINOLINES; NAPHTHALIMIDES; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0035057872     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: A common missense mutation among Japanese, Koreans and Chinese
2. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese
3. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome
4. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
5. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11
6. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion
7. Evaluating the role of polymorphic drug-metabolizing enzymes in the pharmaceutical industry - Impact on drug candidate selection and advancement
8. Genotype/phenotype discordance for human arylamine acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans
9. Racial variability in the UDP-glucuronosyltransferase I (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
10. Molecular mechanisms of slow acetylation of drugs and carcinogens in humans
11. Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases
12. Pharmacogenetics in cancer etiology and chemotherapy
13. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase I in Gilbert's syndrome
14. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation
15. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity
16. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver
17. Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage
18. Polymorphisms and deficient drug metabolism as triggers of toxic reactions
19. Two new alleles in the promoter of the bilirubin UDP-glucuronosyl transferase I (UGT1A1) gene
20. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
21. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans
22. Association of CYP3A4 genotype with treatment-related leukemia
23. Monomorphic and polymorphic human arylamine N-acetyltransferases. A comparison of liver isozymes and expressed products of two cloned genes
24. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
25. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
26. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates
27. Genotyping human polymorphic arylamine N-acetyltransferase: Identification of new slow allotypic variants
28. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
29. 8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome
30. High variability in SN-38 glucuronidation in liver samples from African population as predicted by UGT1A1 genotypes
31. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
32. UGT1A1 promoter genotype correlates with pharmacokinetics of irinotecan (CPT-11)
33. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
34. Pharmacogenetics and cancer chemotherapy
35. Molecular biology of bilirubin metabolism
36. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
37. Three Japanese patients with Crigler-Najjar syndrome type I carry an identical nonsense mutation in the gene for UDP-glucuronosyltransferase
38. The clinical pharmacology of 6-mercaptopurine
39. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
40. Gilbert syndrome caused by a homozygous missense mutation (Tyr486Asp) of bilirubin UDP-glucuronosyltransferase gene
41. UGT1*1 genotyping in a Canadian Inuit population
42. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
43. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia
44. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver
45. Population studies on Gilbert's syndrome
46. Genetic control of isoniazid metabolism in man
47. Phase I study of amonafide dosing based on acetylator phenotype
48. Paradoxical relationship between acetylator phenotype and amonafide toxicity
49. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender
50. Population pharmacodynamic study of amonafide: A Cancer and Leukemia Group B study
51. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
52. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
53. Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes
54. The genetic basis of Gilbert's syndrome
55. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin UDP-glucuronosyltransferase
56. Predicted homozygous mis-sense mutation in Gilbert's syndrome
57. Drug metabolism polymorphisms as modulators of cancer susceptibility
58. Severe CPT-II toxicity in patients with Gilbert's syndrome: Two case reports
59. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region